Bart Neyns obtained his MD (1992) and PhD (2001) from the Vrije Universiteit Brussel (VUB), Brussels. Dr Neyns held a Research Fellowship supported by the National Fund for Scientific Research (NFWO), at the Laboratory of Medical Oncology, VUB (1992–1996). In 1996, he began furthering his training in Internal Medicine and Medical Oncology, at the same institute, obtaining his Specialist Degree in 1999. Dr Neyns subsequently became a Resident at the Department of Internal Medicine/Medical Oncology, VUB (1999–2002). In 2009, Dr Neyns specialized in Medical Oncology. During 2002–2012 and 2012-2019, he was appointed respectively as Head of Clinic and Head of Division at the Department of Medical Oncology, UZ Brussel, before being appointed to his current position as Head of Department at the same department, in May 2019. He currently holds an additional parallel position as Clinical Professor at the Faculty of Medicine and Pharmacy, VUB (since 2007); between 2010 and 2018 he served as a Dermato-Oncology Consultant at the Erasme Hospital Université Libre de Bruxelles (ULB), Brussels. Dr Neyns is the member of seven national and international scientific societies including, the Belgian Medical Society of Medical Oncology ESMO, and ASCO. He has been the recipient of several competitive research grants, and has considerable clinical trial experience as a Principal Investigator for more than fifteen academia sponsored clinical trials for patients with advanced melanoma, glioma and colorectal cancer; including clinical trials with a proprietary autologous dendritic cell therapy (TriMixDC) and first-in-human phase I clinical trials with intratumoral injection of autologous myeloid dendritic cells. Dr Neyns has an extensive publication record as the (co-)author of over hundred forty primary manuscripts published in peer review medical journals (incl. N Engl J Med, Lancet Oncol, and the J Clin Oncol), and has been invited speaker at several international congresses. His current research interests broadly include the immune- and targeted therapy of melanoma and the treatment of patients with malignant glioma with a strong emphasis on conducting academia sponsored trials.